Evidence map›Paper›PMID 25151481›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014

The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett.

Brad Spellberg, David N Gilbert

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled prevalence of Escherichia coli phenotypic and genotypic antimicrobial resistance profiles in poultry: systematic review and meta-analysis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Biogenesis of Au Nanoparticles from Plant-Derived Metabolites -ACS biomaterials science & engineering · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Brad SpellbergDivision of Infectious Diseases, Keck School of Medicine at the University of Southern California (USC), and the LAC + USC Medical Center, Los Angeles, CA.
David N GilbertDepartment of Medical Education, Providence Portland Medical Center and Oregon Health Sciences University, Portland.

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Humanized Monoclonal Antibody to Treat Acinetobacter InfectionsR42AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI ISLAM, KHALID · 2016 to 2018
$3.1M
A New Approach to Staphylococcus aureus Vaccine Development - Resubmission 01R01AI103342 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI DAUM, ROBERT S., LEE, JEAN CLAIRE · 2013 to 2016
$2.1M
Activated Targeted Killer (ATAK) Cells for Invasive Fungal InfectionsR01AI081719 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SPELLBERG, BRAD J · 2009 to 2013
$1.7M
Humanized Monoclonal Antibodies to Treat Acinetobacter InfectionsR41AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI SPELLBERG, BRAD J · 2013 to 2014
$574k
Acinetobacter virulence and host innunopathogenesisR21AI101750 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2013 to 2014
$434k
Antibody Targeting of KPC and NDM1R21AI101492 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2013 to 2014
$417k
NIAID NIH HHS R01 AI081719NIAID NIH HHS R01 AI103342NIAID NIH HHS R21 AI101492NIAID NIH HHS R21 AI101750NIAID NIH HHS R41 AI106375NIAID NIH HHS R42 AI106375NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

The ways we have developed, used, and protected antibiotics have led, predictably, to our current crisis of rising antibiotic resistance and declining new treatments. If we want to stave off a postantibiotic era, we need to fundamentally change our approach. We need to challenge long-standing assumptions and cherished beliefs. We need to push through the reflexive resistance and excuses (eg, "that's not how we do things" and "that can't be done") that result from challenging established ways. Excuses abound. Action is needed. Ultimately, we need a coordinated national action plan to combat resistance. Herein we discuss 7 tasks and 3 common themes that cut across those tasks, which are necessary to achieve long-term success in dealing with antibiotics and resistance. These principles derive from many years of dialogue with Dr John Bartlett. The field of infectious diseases, and indeed medicine in general, has benefited immeasurably from his remarkable leadership.

Indexed as

Drug Resistance, MicrobialAgricultureAnimalsAnti-Bacterial AgentsDrug UtilizationHumansVeterinary DrugsAnti-Bacterial AgentsVeterinary Drugsantibioticsfuturepoliciesresistance

Identifiers

PMID25151481
PMCPMC4176319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.